For decades, the UK’s pharmaceutical and biotech sectors have been leaders in discovery and innovation.
Yet as the cost of bringing innovation to market increases and global competition intensifies, the need for targeted investment to support breakthrough science has never been clearer.
That is why the UK government’s renewal of the Biomedical Catalyst, combined with the Life Sciences Innovation Manufacturing Fund (LSIMF) and the new Life Sciences Transformational R&D Investment Fund (TRIF) pilot, is so timely.
Check out the rest of the feature here
